Antiviral Regimens for the Patients with Chronic Hepatitis C Virus Complicated with Cirrhosis
- VernacularTitle:慢性丙型肝炎合并肝硬化的抗病毒方案
- Author:
Zhifang RAO
;
Wangang WANG
;
Zhenlin CHENG
;
Zhi WANG
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis C virus;
Liver cirrhosis;
Protease inhibitors;
Polymerase inhibitors;
Interferon-free
- From:
China Pharmacist
2016;19(2):357-359
- CountryChina
- Language:Chinese
-
Abstract:
The efficacy of patients infected with hepatitis C virus complicated with cirrhosis is not promising after treated with present standard therapy. With more and more new drugs against hepatitis C virus, many new regimens for the patients with chronic hepatitis C virus complicated with cirrhosis have come forth. Because the adverse reactions of the first generation HCV protease inhibi-tors telaprevir and boceprevir are severe, they are not recommended to be used in the patients with chronic hepatitis C virus complicated with cirrhosis. The other drugs, such as simeprevir, sofosbuvir and ledipasvir show good efficacy in the patients with chronic hepatitis C virus complicated with cirrhosis, however, the sustained virological response ( SVR) in the patients with chronic hepatitis C virus complicated with cirrhosis is lower than that in the patients with chronic hepatitis C virus without cirrhosis. Therefore, the regimens should be optimized in the future to narrow the gap in SVR.
